Incyte Corp.

NASDAQ:INCY  
65.55
-0.23 (-0.35%)
Products, Strategic Combinations

Syndax Pharmaceuticals And Incyte Announce Global Collaboration To Develop And Commercialize Axatilimab For Chronic Graft-Versus-Host Disease And Other Fibrotic Diseases

Published: 09/27/2021 10:12 GMT
Incyte Corp. (INCY) - Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-versus-host Disease and Other Fibrotic Diseases.
Syndax Pharmaceuticals Inc - Syndax to Receive $ 152 Million in Cash.
Syndax - Two Companies Expect to Expand Development of Axatilimab in Cgvhd With Additional Monotherapy and Combination Trials Planned in 2022.
Syndax Pharmaceuticals Inc - Incyte to Lead U.S. and Global Commercial Activities; Syndax Retains Option to Co-promote in U.S.syndax Pharmaceuticals Inc - Companies Will Participate in a 50:50 Profit Share in U.S.syndax Pharmaceuticals Inc - Syndax Will Receive Double-digit Royalties on Sales Outside of U.S.syndax - Will Also Be Eligible to Receive Up to an Additional $450 Million in Potential Regulatory, Development and Commercial Milestone Payments.